Filing Details

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

 

Tandem Diabetes Care, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

875372 104

(CUSIP Number)

February 13, 2018

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

---

SCHEDULE 13G

 

CUSIP No. 875372 104		Page 2 of 4 Pages

 

1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)   DexCom, Inc.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a)  ☐        (b)  ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware, U.S.A.

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER   2,500,000
				6		SHARED VOTING POWER
				7		SOLE DISPOSITIVE POWER   2,500,000
				8		SHARED DISPOSITIVE POWER

9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   2,500,000
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)  ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)   5.6%
12		TYPE OF REPORTING PERSON (See Instructions)   CO

 

---

SCHEDULE 13G

 

CUSIP No. 875372 104		Page 3 of 4 Pages

Item 1.

 

(a)

Name of Issuer:

Tandem Diabetes Care, Inc.

 

(b)

Address of Issuers Principal Executive Offices:

11045 Roselle Street

San Diego, CA 92121

 

Item 2.

 

(a)

Name of Person Filing:

DexCom, Inc.

 

(b)

Address of Principal Business Office:

6340 Sequence Drive

San Diego, CA 92121

 

(c)

Citizenship:

Delaware, U.S.A.

 

(d)

Title of Class of Securities:

Common Stock

 

(e)

CUSIP Number:

875372 104

 

Item 3.

Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):

Not applicable.

 

Item 4.

Ownership.

 

(a)

Amount beneficially owned:

2,500,000

 

(b)

Percent of class:

5.6%

---

(c)

Number of shares as to which the person has:

 

		(i)		Sole power to vote or to direct the vote:		2,500,000
		(ii)		Shared power to vote or to direct the vote:		0
		(iii)		Sole power to dispose or to direct the disposition of:		2,500,000
		(iv)		Shared power to dispose or to direct the disposition of:		0

 

Item 5.

Ownership of Five Percent or Less of a Class.

Not Applicable.

 

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

 

Item 7.

Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group

Not applicable.

 

Item 9.

Notice of Dissolution of Group

Not applicable.

 

Item 10.

Certifications

Not applicable.

---

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

				DEXCOM, INC.
Dated: February 23, 2018				By:		/s/ Quentin Blackford
				Name:		Quentin Blackford
				Title:		Chief Financial Officer